Docetaxel is an anticancer agent that is used widely in the treatment of breast, prostate, gastric, head and neck, and lung cancer. In the product label for Taxotere (docetaxel), a variety of doses ranging from 60-100 mg/m² are approved for therapeutic use for these various indications, administered as a 1-hour infusion once every 3 weeks. Oradoxel Phase 1 studies are well underway in both New Zealand and the United States. These Phase 1 studies have been successful in identifying a dosing regimen suitable for a Phase 2 study, which we are planning to initiate in the first half of 2019.

Clinical Trial Pipeline

Oradoxel Territory Indication Sponsor/Partner Pre-Clinical Phase I Phase II Phase III
KX-ORADOX-002 New Zealand Prostate Athenex/Zentech
KX-ORADOX-003 United States Solid Tumor Athenex
Planned 1H/2019